Marijuana for PTSD: DEA Inspects Johns Hopkins Trial Site

On January 14, 2016, officials from the local field office of the U.S. Drug Enforcement Administration (DEA) completed their inspection of the Johns Hopkins University trial site in Baltimore, Maryland, for our upcoming study of smoked marijuana for symptoms of PTSD in U.S. veterans. The DEA officials found no issues with the site. The protocol is now awaiting federal DEA approval. The study protocol will be cleared by the Institutional Review Board at Johns Hopkins upon DEA approval. This study is a multi-site Phase 2 drug development trial led by Coordinating Principal Investigator (PI) Marcel Bonn-Miller, Ph.D., with half of the 76 participants treated at the Johns Hopkins site led by Site PI Ryan Vandrey, Ph.D., and the other half treated at a site in Phoenix, Arizona, led by Site PI Sue Sisley, M.D. Renovations and construction at the Phoenix site are expected to be completed in February 2016, followed by DEA inspections. Once the DEA approves the study, we will be able to finalize the contact with the state of Colorado to receive funding, and then order the marijuana for the study from the National Institute on Drug Abuse (NIDA).